Morgan Stanley Initiates Coverage On Mirum Pharmaceuticals with Overweight Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has initiated coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with an Overweight rating and set a price target of $60.
November 13, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley initiated coverage on Mirum Pharmaceuticals with an Overweight rating and a price target of $60, indicating a positive outlook for the stock.
The initiation of coverage by Morgan Stanley with an Overweight rating typically suggests a positive outlook on the stock's performance. The price target of $60 implies a significant upside from the current trading price, which could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100